2026 Volume: 02 Issue: 06 www.ijrpa.com ISSN 2456-9995 Research Article

International Journal Research Publication Analysis

Page: 01-14

CRISPR-BASED GENE EDITING AS A FUTURE PHARMACOLOGICAL TOOL: PROSPECTS AND LIMITATIONS

H. Kalyankumar*[1], P. Madhumayadevi[2], Dr. V. Kalvimoorthi[3], L.Gopi[4]

[1] M.Pharm First Year, [2]Assistant Professor Department of Pharmacology.

[3]Professor Cum HOD Department of Pharmaceutics,

[4]Assistant Professor Department of Pharmaceutics.

Aadhi Bhagawan College of Pharmacy, Rantham, Thiruvannmalai, Tamilnadu.

Article Received: 01 June 2026
Article Revised: 20 June 2026
Published on: 09 July 2026

***Corresponding Author: H. Kalyankumar**
M.Pharm First Year, Aadhi Bhagawan College of Pharmacy, Rantham, Thiruvannmalai, Tamilnadu.

DOI: https://doi-doi.org/101555/ijrpa.6693

ABSTRACT

Background

CRISPR-Cas genome editing is a powerful and programmable tool that enables precise modification of genetic sequences and has significant therapeutic potential in pharmacology.

Objective

To review the mechanisms, clinical applications, and limitations of CRISPR-based gene editing in precision medicine.

Methods

Relevant literature from scientific databases was analyzed focusing on molecular mechanisms, therapeutic advances, and safety challenges.

Results

CRISPR mediates targeted genome modification through sgRNA-guided Cas nucleases with DNA repair via NHEJ or HDR. Advanced approaches such as base and prime editing improve precision. Clinical studies demonstrate promising applications in genetic diseases and oncology; however, off-target effects, delivery barriers, and immunogenicity remain major limitations.

Conclusion

CRISPR holds strong potential for therapeutic innovation, but further optimization and safety validation are required for broader clinical application.

KEYWORDS: Crispr; Gene editing; Precision medicine; Gene therapy; Pharmacology; Genome engineering; Base editing; Prime editing; Off-target effects; CAR-T therapy; Molecular therapeutics.

1. INTRODUCTION

The emergence of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has revolutionized molecular biology and therapeutic pharmacology. Initially discovered as part of the bacterial adaptive immune defense system, CRISPR-associated (Cas) proteins recognize and cleave invading viral DNA. This natural mechanism was later engineered into a programmable genome-editing platform, transforming biomedical research and therapeutic development.

The adaptation of CRISPR-Cas9 in 2012 marked a major breakthrough in genome engineering by enabling precise, rapid, and cost-effective genetic modification. Compared with earlier technologies such as zinc-finger nucleases (ZFNs) and TALENs, CRISPR offers greater simplicity, efficiency, and multiplexing capability. These advantages have positioned it at the forefront of next-generation pharmacological innovation.



Figure 1: CRISPR Gene Editing.

Conventional pharmacology primarily targets proteins using small molecules or biologics; however, many disorders—including monogenic diseases, inherited metabolic conditions, and certain cancers—arise from underlying genetic mutations that cannot be fully addressed by traditional therapies. CRISPR introduces a paradigm shift by enabling correction or modification of disease-causing genes at the genomic level, moving treatment strategies toward potentially curative interventions rather than symptomatic control.

Mechanistically, CRISPR systems employ a single guide RNA (sgRNA) to direct a Cas nuclease to a complementary DNA sequence adjacent to a protospacer adjacent motif (PAM). The induced double-stranded break is repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR), allowing gene disruption or precise correction. Recent developments, including base editing and prime editing, further enhance precision while reducing genomic instability.



Figure 2: CRISPR-Cas9 Mechanism.



Figure 3: CRISPR In Drug Discovery Workflow.

Beyond basic research, CRISPR has expanded into drug target identification, disease modeling, CAR-T cell optimization, and pharmacogenomic studies. Clinically, early-phase trials for disorders such as sickle cell disease and β-thalassemia demonstrate promising therapeutic outcomes, particularly through ex vivo stem cell editing approaches. Despite its transformative potential, challenges remain, including off-target effects, delivery limitations, immunogenicity, and ethical concerns—particularly regarding germline editing. Addressing these issues through improved specificity, safer delivery systems, and regulatory oversight is essential for broader clinical translation. Overall, CRISPR represents a powerful and evolving therapeutic platform with the potential to redefine modern pharmacology through precision genome engineering.

2. MECHANISM OF CRISPR-BASED GENE EDITING

CRISPR-based genome editing, most commonly mediated by the CRISPR-Cas9, proceeds through a coordinated sequence of molecular events that enable precise modification of DNA within living cells.

Target Recognition: The first step involves sequence-specific targeting of the genomic DNA. A single guide RNA (sgRNA), engineered to contain a 20-nucleotide sequence complementary to the target DNA region, forms a complex with the Cas9 protein. For successful binding, the target DNA must be located adjacent to a short conserved sequence known as the protospacer adjacent motif (PAM), typically 5′-NGG-3′ in the commonly used Streptococcus pyogenes Cas9 system. The presence of the PAM ensures specificity and prevents self-targeting. Once the sgRNA base-pairs with the complementary DNA strand, Cas9 undergoes conformational activation, positioning its nuclease domains for cleavage.

DNA Cleavage: Upon accurate target recognition, Cas9 introduces a site-specific double-strand break (DSB) in the DNA. The enzyme contains two catalytic domains:

- The **HNH domain**, which cleaves the DNA strand complementary to the guide RNA.
- The **RuvC domain**, which cleaves the non-complementary strand.

The coordinated activity of these domains generates a blunt-ended DSB at the target locus. This controlled DNA break is the critical event that triggers the cell's endogenous DNA repair machinery and enables genome modification.

DNA Repair Mechanisms: Following cleavage, the cell repairs the DSB through one of two major pathways:

a) Non-Homologous End Joining (NHEJ)

NHEJ is a rapid but error-prone repair mechanism that directly ligates the broken DNA ends. This process frequently introduces small insertions or deletions (indels) at the break site.

Such mutations can disrupt the reading frame of a gene, leading to loss of function or gene knockout. NHEJ is widely used in research for gene inactivation studies.



Figure 4: Mechanism Of CRISPR-Based Gene Editing And Its Advanced Modalities.

b) Homology-Directed Repair (HDR)

HDR is a high-fidelity repair pathway that operates in the presence of a homologous DNA template. By providing an exogenous donor template containing the desired genetic modification, researchers can introduce precise sequence corrections, insertions, or replacements. HDR is particularly valuable for therapeutic gene correction strategies.

Advanced CRISPR Platforms

To enhance precision and reduce potential risks associated with double-strand breaks, advanced CRISPR technologies have been developed:

- **Base Editing:** Enables direct conversion of one nucleotide to another (e.g., C→T or A→G) without generating a DSB, thereby minimizing unintended mutations.
- **Prime Editing:** Utilizes a modified Cas enzyme fused with reverse transcriptase to introduce precise insertions, deletions, or base substitutions without relying on donor templates or double-strand cleavage.

These next-generation systems improve editing accuracy and safety, expanding the therapeutic potential of CRISPR-based pharmacological applications. Overall, CRISPR gene editing functions as a programmable molecular tool that identifies a specific DNA sequence, introduces a targeted break, and harnesses cellular repair pathways to achieve gene disruption or precise genetic modification.

3. PROSPECTS OF CRISPR IN PHARMACOLOGY

Gene Therapy For Genetic Disorders: CRISPR-based gene editing offers a transformative approach for treating monogenic disorders by directly correcting disease-causing mutations at the DNA level. Unlike conventional pharmacotherapy, which primarily manages symptoms, CRISPR has the potential to provide long-term or permanent cures. In hematological diseases such as sickle cell disease and beta-thalassemia, ex vivo editing of hematopoietic stem cells has shown significant clinical success. Modified stem cells are reinfused into patients, leading to sustained production of functional hemoglobin and reducing dependence on lifelong drug therapy or transfusions. Similar strategies are being explored for cystic fibrosis and Duchenne muscular dystrophy through targeted gene correction or exon modification. Although challenges in efficient in vivo delivery remain, ongoing advances in viral vectors and lipid nanoparticles are improving therapeutic feasibility.

Oncology Applications: CRISPR plays a major role in cancer research and immuno-oncology. It enables restoration of tumor suppressor genes and disruption of oncogenes that drive tumor growth. Additionally, CRISPR enhances the development of engineered CAR-T cells by improving targeting precision and reducing immune-related side effects. Genome-wide CRISPR screening also helps identify genes involved in drug resistance, metastasis, and tumor survival pathways. This accelerates the discovery of novel anticancer drug targets and supports personalized treatment strategies, strengthening its role in precision oncology.



Figure 5: Prospects Of CRISPR In Pharmacology.

Infectious Diseases: CRISPR systems are being investigated as antiviral tools capable of directly targeting viral genetic material. DNA-targeting systems such as Cas9 have shown potential in disrupting integrated viral genomes in chronic infections like HIV and hepatitis B. RNA-targeting systems such as Cas13 can degrade viral RNA without altering host DNA, offering a potentially safer therapeutic option. While delivery efficiency and viral mutation remain challenges, CRISPR-based antiviral strategies may complement or enhance existing pharmacological treatments.

Drug Discovery and Target Identification: CRISPR has significantly accelerated drug discovery through genome-wide knockout and activation screens. These high-throughput platforms enable identification of novel drug targets, mapping of disease pathways, and understanding of resistance mechanisms. Compared to earlier gene-silencing methods, CRISPR provides higher precision and more reliable target validation, making it a powerful tool in modern pharmacological research and pharmaceutical development.

Precision and Personalized Medicine: CRISPR supports precision medicine by enabling correction of patient-specific mutations and facilitating individualized therapeutic design. It also aids pharmacogenomic studies by modeling genetic variations to predict drug response and toxicity.

As genomic data becomes increasingly integrated into clinical practice, CRISPR-based interventions are expected to become central to personalized pharmacotherapy.

4. LIMITATIONS AND CHALLENGES

Despite its transformative potential, CRISPR-based gene editing faces several scientific, clinical, and ethical challenges that must be addressed before it can become a routine pharmacological therapy.

Off-Target Effects: One of the most significant safety concerns in CRISPR technology is off-target editing. Although CRISPR–Cas systems are designed to target specific DNA sequences, unintended cleavage may occur at genomic sites with partial sequence similarity. Such off-target activity can result in unwanted mutations, chromosomal rearrangements, insertions, deletions, or activation of oncogenes, potentially leading to genomic instability or tumorigenesis. Advancements such as improved single guide RNA (sgRNA) design algorithms, high-fidelity Cas9 variants, and base/prime editing technologies have significantly reduced off-target risks. However, complete elimination of unintended edits remains a challenge, particularly in complex in vivo systems. Long-term monitoring is therefore essential to ensure genomic safety.

Delivery Challenges: Efficient and targeted delivery of CRISPR components to specific tissues remains one of the greatest barriers to clinical translation. The therapeutic effectiveness of CRISPR largely depends on safe and precise delivery of Cas proteins and guide RNAs into target cells.

Currently used delivery systems include:

- **Viral vectors** (e.g., adeno-associated virus [AAV], lentivirus), which provide high transduction efficiency but are limited by packaging capacity, potential insertional mutagenesis, and immune responses.
- **Lipid nanoparticles (LNPs)**, which offer non-viral delivery options but may have limited tissue specificity and transient expression.
- **Electroporation**, mainly used in ex vivo editing of cells such as hematopoietic stem cells, which is effective but not suitable for direct in vivo applications.

Achieving efficient, tissue-specific, and minimally immunogenic delivery remains a major research focus in CRISPR pharmacology.

Immunogenicity: Another important concern is immune recognition of CRISPR-associated (Cas) proteins. Since many Cas proteins are derived from bacterial species, pre-existing immunity in humans may trigger immune responses upon administration. This can reduce editing efficiency and pose safety risks, including inflammation or immune-mediated toxicity. Immune reactions are particularly problematic for repeated dosing, which may be necessary in certain therapeutic settings. Strategies such as transient Cas expression, protein engineering, and use of less immunogenic Cas variants are being explored to minimize immune-related complications.

Ethical and Regulatory Concerns: CRISPR gene editing raises profound ethical questions, especially regarding germline editing, where genetic changes can be inherited by future generations. While somatic cell editing for therapeutic purposes is generally more accepted, germline modification remains highly controversial. Ethical debates intensified following controversial human embryo editing cases, highlighting the potential misuse of genome-editing technologies. Concerns include unintended long-term effects, equity of access, genetic enhancement, and societal implications. Additionally, regulatory frameworks differ across countries, creating inconsistencies in clinical trial approval and oversight. Clear global guidelines and strict governance are necessary to ensure responsible development and application of CRISPR-based therapies.

Genomic Instability and Mosaics: Incomplete or inefficient editing can result in mosaicism, where only a subset of cells carries the desired genetic modification. Mosaic outcomes may reduce therapeutic efficacy and complicate safety assessment.



Figure 6: Limitations Of CRISPR.

Furthermore, double-strand DNA breaks induced by CRISPR can activate cellular DNA damage responses, potentially leading to chromosomal abnormalities or unintended large genomic deletions. These risks emphasize the importance of improving editing precision and developing alternative approaches such as base editing and prime editing, which minimize double-strand breaks.

Overall Perspective: Although CRISPR offers unprecedented opportunities in pharmacology, addressing safety, delivery, immune, and ethical challenges is essential for its successful clinical translation. Continued technological refinement, rigorous clinical trials, and comprehensive regulatory oversight will determine its long-term role in therapeutic medicine.

5. EMERGING INNOVATIONS TO OVERCOME LIMITATIONS:

Continuous advancements in CRISPR technology are addressing its major limitations and improving its safety, precision, and clinical applicability. These innovations are critical for translating CRISPR from experimental research into reliable pharmacological therapy.

High-fidelity Cas9 variants have been engineered to significantly reduce off-target cleavage while maintaining efficient on-target editing. These improved nucleases enhance genomic accuracy and minimize unintended mutations, making therapeutic applications safer.

Base editing and prime editing represent major breakthroughs because they allow precise nucleotide modifications without inducing double-strand DNA breaks. This reduces the risk of genomic instability, large deletions, and chromosomal rearrangements while enabling correction of point mutations responsible for many genetic disorders.

Advances in delivery systems are equally important. **Tissue-specific nanoparticles** and improved viral or non-viral vectors increase targeted delivery to diseased cells while limiting systemic exposure and immune activation. Optimizing delivery remains essential for effective in vivo gene editing.

Regulatory approaches such as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) provide reversible control of gene expression without permanently altering DNA. These tools are valuable for functional studies and therapeutic modulation where permanent editing is not required.

RNA editing platforms further expand therapeutic options by targeting gene expression at the transcript level, offering a safer alternative in certain conditions.

Together, these innovations significantly enhance precision, reduce safety risks, and strengthen the clinical potential of CRISPR in modern pharmacology.

6. FUTURE DIRECTIONS

The future development of CRISPR technology in pharmacology is focused on improving accuracy, safety, scalability, and clinical translation. Continued research and technological refinement will determine its integration into routine therapeutic practice.

One important direction is the integration of artificial intelligence and computational biology for optimized single-guide RNA (sgRNA) design. AI-based prediction models can improve target specificity, reduce off-target effects, and enhance editing efficiency by analysing genomic sequences and predicting optimal targeting sites.



Figure 7: Future Directions of CRISPR In Pharmacology.

Another critical area is the development of safer and more efficient delivery systems. Advances in tissue-specific viral vectors, improved lipid nanoparticles, and novel non-viral delivery platforms aim to enhance targeted gene editing while minimizing immune reactions and systemic toxicity. Effective delivery remains one of the most important challenges for widespread clinical application. Expansion into epigenome editing represents a promising future approach. Instead of permanently altering DNA sequences, epigenetic modulation allows reversible regulation of gene expression. This approach may reduce long-term genomic risks while providing therapeutic control over disease-related genes.

Combination therapies involving CRISPR and conventional pharmacological drugs are also gaining attention. CRISPR can be used to enhance drug sensitivity, overcome resistance, or modify disease pathways, thereby improving the efficacy of existing treatments. Such integrative strategies may provide synergistic therapeutic benefits. Furthermore, wider validation through large-scale clinical trials is essential to establish long-term safety, efficacy, and regulatory approval. Increasing clinical evidence will strengthen confidence in CRISPR-based therapies and support their adoption in mainstream medicine. As research progresses and technological barriers are reduced, CRISPR has the potential to transition from an experimental genetic tool to a widely accepted and transformative pharmacological intervention.

7. CONCLUSION

CRISPR-based gene editing represents a significant advancement in therapeutic pharmacology. It enables precise and targeted modification of genetic material, offering new possibilities for treating genetic disorders, cancer, and infectious diseases at their molecular cause rather than only managing symptoms. The technology holds great promise for developing curative treatments and improving personalized medicine approaches. However, several important challenges must be addressed before it can be widely applied in routine clinical practice. These include off-target effects that may cause unintended genetic changes, limitations in safe and efficient delivery to target tissues, immune responses against CRISPR components, and ethical concerns related to genome editing. To ensure safe implementation, continued technological improvements, extensive preclinical and clinical trials, and strict ethical and regulatory oversight are essential. With ongoing research and innovation, CRISPR has the potential to become a powerful and reliable tool in future pharmacological therapy and precision medicine.

8. REFERENCES

1. Frangoul H, Altshuler D, Cappellini MD, *et al.,*CRISPR–Cas9 gene editing for sickle cell disease and β-thalassemia.*New England Journal of Medicine.* 2021;384(3):252–260. DOI: 10.1056/NEJMoa2031054
2. Gillmore JD, Gane E, Taubel J, *et al.,*CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis.*New England Journal of Medicine.* 2021;385(6):493–502. DOI: 10.1056/NEJMoa2107454
3. Li C, Cao Y, Cheng Y, *et al.,*Advances and challenges in CRISPR-based therapeutic genome editing.*Theranostics.* 2022;12(3):1234–1256.DOI: 10.7150/thno.69527
4. Li T, Huang S, Jiang WZ, *et al.,*CRISPR/Cas9 therapeutics: progress and prospects. *Signal Transduction and Targeted Therapy.* 2023;8(1):36. DOI: 10.1038/s41392-023-01309-7
5. Wang JY, Doudna JA.CRISPR technology: A decade of genome editing is only the beginning.*Science.* 2023;379(6631):eadd8643.DOI: 10.1126/science.add8643
6. Xu X, Wan T, Xin H, *et al.,*CRISPR/Cas9 delivery strategies for therapeutic genome editing.*Advanced Drug Delivery Reviews.*2023;194:114735. DOI: 10.1016/j.addr.2023.114735
7. Pacesa M, *et al.,*Past, present and future of CRISPR genome editing technologies. *Cell.* 2024;187(3):568–590.DOI: 10.1016/j.cell.2024.01.011

8. Kim HS, *et al.,*Recent advances in CRISPR-based functional genomics tools. *Experimental & Molecular Medicine.*2024;56:101–118.
DOI: 10.1038/s12276-024-01212-3
9. Azeez SS, *et al.,*Advances in CRISPR-Cas technology and therapeutic applications. *Frontiers in Genome Editing.*2024;6:1509924.DOI: 10.3389/fgeed.2024.1509924
10. Cetin B, *et al.,*Advancing CRISPR genome editing into gene therapy clinical applications.*International Journal of Medical Sciences.*2025;22:3625–3640.
DOI: 10.7150/ijms.100234
11. Far BF, *et al.,*CRISPR Technology in Disease Management.*Biomedicines.* 2025;13(2):410.DOI: 10.3390/biomedicines13020410
12. **12.**Tang S, *et al.,*Overcoming delivery challenges in CRISPR/Cas9 gene editing. *International Journal of Medical Sciences.*2025;22:3625–3638.
DOI: 10.7150/ijms.102567
13. Khoshandam M, *et al.,*CRISPR/Cas9 genome-editing system: Clinical applications and delivery methods.*Journal of Translational Medicine.*2023;21:521.
DOI: 10.1186/s12967-023-04132-5
14. Li T, Huang S, Jiang WZ, *et al.,*CRISPR/Cas9 therapeutics: Progress and prospects. *Signal Transduction and Targeted Therapy.*2023;8:36.
DOI: 10.1038/s41392-023-01309-7
15. Aljabali AAA, *et al.,*Principles of CRISPR-Cas9 technology: Advancements in genome engineering.*Biomedicine & Pharmacotherapy.*2024;169:115012.
DOI: 10.1016/j.biopha.2024.115012
16. Kim HS, *et al.,*Recent advances in CRISPR-based functional genomics tools. *Experimental & Molecular Medicine.*2024;56:101–118.
DOI: 10.1038/s12276-024-01212-3
17. Joo JH, *et al.*,Precision gene editing: The power of CRISPR-Cas systems in therapeutics.*Biomedicines.* 2025;13(1):102.DOI: 10.3390/biomedicines13010102
18. Far BF*, et al.,*CRISPR technology in disease management: Updated review. *Biomedicines.* 2025;13(2):410.DOI: 10.3390/biomedicines13020410
19. Cetin B, *et al.,* Advancing CRISPR genome editing into gene therapy clinical applications.*International Journal of Medical Sciences.*2025;22:3625–3640.
DOI: 10.7150/ijms.100234
20. Srivastav AK, *et al*.,Transforming pharmacogenomics using CRISPR-based precision medicine. *Frontiers in Pharmacology.* 2025; 16:1321456.

DOI: 10.3389/fphar.2025.1321456

21. Zhang Y, *et al.,*CRISPR-Cas9 technology in tumor genome editing and drug development .*Frontiers in Pharmacology.* 2025; 16:1552741.
    DOI: 10.3389/ fphar.2025.1552741
22. Chen Y, *et al.,* Therapeutic applications of CRISPR-Cas9 gene editing. *Frontiers in Genome Editing.*2025;7:1724291.DOI: 10.3389/fgeed.2025.1724291
23. Agboola OE, *et al.,*AI-driven CRISPR genome engineering for drug discovery. *Biochemical Pharmacology.*2025;222:115678.DOI: 10.1016/j.bcp.2025.115678
24. Gwon LW, *et al.,* Advances in large-scale DNA engineering with CRISPR systems. *Experimental & Molecular Medicine.*2025;57:1–14.DOI: 10.1038/s12276-025-01530-0